Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma

Citation
Jj. Lewis et al., Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma, ARCH SURG, 134(2), 1999, pp. 190-194
Citations number
18
Categorie Soggetti
Surgery,"Medical Research Diagnosis & Treatment
Journal title
ARCHIVES OF SURGERY
ISSN journal
00040010 → ACNP
Volume
134
Issue
2
Year of publication
1999
Pages
190 - 194
Database
ISI
SICI code
0004-0010(199902)134:2<190:MAOLF(>2.0.ZU;2-2
Abstract
Background: The majority of survival studies in patients with extremity sof t tissue sarcoma have focused on early recurrence and mortality. There are few data addressing long-term follow-up and survival. Objective: To analyze survival and recurrence in patients with extremity so ft tissue sarcoma who survive for more than 5 years. Methods: Patients who underwent treatment for primary tumors (July 1982 to July 1994) and were followed up for more than 5 years were the subject of s tudy. Disease-specific and disease-free survival were determined actuariall y. Significance was evaluated using log-rank testing for univariate analysi s and Cox model stepwise regression for multivariate analysis. Results: A total of 495 patients with primary extremity rumors were treated before July 1989 and eligible for 5-year follow-up. Of these, 282 have bee n followed up for more than 5 years (median follow-up, 84.4 months). Actuar ial disease-specific survival of patients who survive for longer than 5 yea rs was 79% +/- 7% (+/-SEM) at 10 years, and of those who were metastasis fr ee at 5 years was 91% +/- 4% at 10 years. On univariate analysis, post-5-ye ar disease-specific survival was influenced by positive microscopic margin and initial tumor size of 5 cm or greater. On multivariate analysis, post-5 -year disease-specific survival was influenced only by positive margins. Conclusions: Based on these analyses, 21% of patients with primary extremit y sarcoma who survive for 5 years will die of disease within 5 years. Even of those who are metastasis free at 5 years, 9% will die of disease within 5 years. In contrast to early mortality, tumor grade has no influence on po st-5-year prognosis. Patients with positive microscopic margins are at risk for post-5-year disease-specific mortality and therefore require longterm follow-up and consideration For investigational therapy.